Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Gastrointestinal 7Other hematologic neoplasm 2Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 339Neoplasms, Plasma Cell 62Lymphoma 38Recurrence 27Leukemia 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 20Hodgkin Disease 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 17Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Follicular 16Lymphoma, Large B-Cell, Diffuse 15Immunoglobulin Light-chain Amyloidosis 14Lymphoma, B-Cell, Marginal Zone 13Hematologic Neoplasms 13Lymphoma, Mantle-Cell 12Burkitt Lymphoma 12Lymphoma, Large-Cell, Immunoblastic 10Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myeloid, Accelerated Phase 8Blast Crisis 8Neoplasm, Residual 7Hematologic Diseases 7Pancreatic Neoplasms 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Lung Neoplasms 6

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pathologic Complete Response × Plasma cell × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡